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Abstract
Nano-encapsulation is applied for the preparation of functional food to preserve micronutrients degradation and to ame-
liorate their absorption. Being nano-encapsulation already related to increased vitamin A embryotoxicity, we aimed to 
evaluate the effect of traditionally formulated (BULK-A) and nano-encapsulated vitamin A (NANO-A) in two different 
vertebrate models: rat post implantation Whole Embryo Culture (WEC) and Frog Embryo Teratogenesis Assay-Xeno-
pus (FETAX). After benchmark-dose modelling, WEC results showed that NANO-A was 7 times more effective than 
BULK-A, while FETAX results indicated that X. laevis development was affected only by NANO-A. The relative 
potency of WEC was 14 times the potency of FETAX, suggesting a minor role of preformed vitamin A in X. laevis 
development in respect to mammal embryogenesis. Results from this work prompt the necessity to monitor the use of 
food supplemented with NANO A, since even low doses can elicit teratogenic effects on vertebrate embryos due to its 
increased bioavailability.  
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Introduction
Over the past few decades, the evolution of a number of new technologies has revolution-
ized the food sector. Among these, nanotechnology is an advanced interdisciplinary scien-
tific field that involves the manufacture, processing and application of materials with size 
in the nanometer range[1]. Nano-encapsulation is the coating of various substances within 
another material at sizes on the nano scale. The encapsulation material is known as the ex-
ternal phase, the shell, coating or membrane. The shell ensures higher availability than the 
core components itself, that usually are easily degraded or difficultly transferred across the 
biological membranes[2]. Applications for nano-encapsulation in food industry (nutraceu-
tical production and human or veterinary food fortification) have been increasing because 
of the many advantages that these technologies can confer to the encapsulated materi-
al. It is generally used to deliver different nutraceutical products and bioactive molecules 
such as vitamins and antioxidants, allowing production of functional foods with enhanced 
functionality and stability by protecting the encapsulated materials from environmental, 
enzymatic and chemical changes, as well as ameliorate their organoleptic properties[3]. Lip-
id-based nano-encapsulation systems enhance the performance of lipophilic molecules by 
improving their solubility. In these systems, the lipophilic substance (core) is surrounded 
by an amphiphilic shell (coat) made of surface-active material that enhances solubility 
in aqueous media[4]. Nano-encapsulation provides significant savings to formulators, as it 
allows reducing the amount of active ingredients, increasing their bioavailability and shelf-
life[5]. In addition, it has been proposed that the larger surface area of small lipid droplets 
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facilitates the crossing of biological barriers and allow the en-
capsulated lipophilic substances to quickly and efficiently reach 
the biological targets enhancing their bioavailability[6,7]. On the 
other hand, encapsulation may modify absorption, distribution, 
metabolism, and excretion processes, thereby altering its poten-
tial for promoting toxicity[8].
 Because of the potential toxic effects on human health 
and environment, the increased use of nano-formulations in food 
and beverages has become matter of concern[1,8,9]. Since nano-for-
mulations are essentially different from their corresponding bulk 
formulations, the European Food Safety Agency (ESFA) and the 
Food and Drug Administration (FDA) recommended to careful 
evaluate and monitor nano-formulated molecules and promoted 
the search of valid and rapid methods for the identification, char-
acterization and evaluation of the risks deriving from the use of 
these new substances[10].
 Vitamin A is an essential nutrient which has received 
much attentionas in developed countries it has been supplement-
ed into a variety of foods, leading to excessive vitamin A in-
take[11]. It has been established that the recommended daily dose 
of vitamin A (retinol) is 600 μg/day in adult women, 700 μg/
day in pregnant women and 1000 μg/day during lactation, which 
corresponds to approximately 2000 IU, 2500 IU and 3500 IU re-
spectively. Furthermore, the maximum tolerated dose of retinol 
is 3000 μg/day, which corresponds to about 10000 IU[12]. Plasma 
concentration of retinol is guaranteed constant in normal con-
dition and is close to 1-2 μM, corresponding to about950-2000 
IU/L[13,14]. Hypervitaminosis A is difficult to be obtained by ex-
cessive dietary intake, but is usually a result of consuming an 
excess of preformed vitamin A from supplements[15]. Vitamin 
A values > 4μM (nearly 4000 IU/L) suggest hypervitaminosis 
A and associated toxicity. About 28-37% of general population 
uses supplements containing vitamin A[14], while a relatively 
small number of studies have reported plasma concentrations 
after ingestion of retinol supplements. 
 Vitamin A is obtained from the diet either as preformed 
vitamin A (mainly retinol and retinyl esters) in foods of animal 
origin or as provitamin A carotenoids in plant-derived foods.
Once retinol has been taken up by a cell, it can be oxidized to 
retinal (retinaldehyde) by retinol dehydrogenases and then ret-
inaldehyde can be oxidized to retinoic acid (RA) by aldehyde 
dehydrogenases (ALDHs)[17]. A number of studies demonstrate 
that retinoic acid metabolites mediate most, if not all the toxic 
effect of retinol.
 As far as embryo development is concerned, RA is a 
well-known morphogen and key determinant during embryon-
ic development of both vertebrate and invertebrate chordates 
because of its implication in patterning the anterior-posterior 
axis by controlling the induction of HOX genes expression[18-20]. 
RA levels in embryos tissues are finely controlled by a precise 
balance between ALDH synthetic activity and the metabolizing 
activity of CYP26, a cytochrome P450 enzyme. Consequently, 
alterations of RA levels due to deficiency or excess of vitamin 
A intake cause embryonic defects in different organs includ-
ing eyes, heart, lungs and genital tract, or defects in the ante-
rior-posterior patterning of the neural tubes[18,21]. Perturbation 
of RA levels in rodent embryos during neurulation is reported 
to alter branchial morphogenesis and branchial neural crest cell 
migration, with consequent craniofacial malformations[22-25]. In 
addition, also in the amphibian Xenopus laevis, larvae developed 
from embryos exposed to RA at the neurula stage showed anteri-
or dysmorphogenesis, specifically at the level of the craniofacial 
cartilages of the 1st and 2nd branchial arch[26].
 The rat, by the post implantation rodent Whole Embryo 
Culture (WEC) and the amphibian X. laevis by the Frog Em-
bryo Teratogenesis Assay-Xenopus (FETAX) are here proposed 
to evaluate and compare the effects on embryo development of 
the exposure to bulk and nano-encapsulated vitamin A. The final 
aim is to evaluate alternative tests in order to reconsider vitamin 
hazard evaluation after nano-encapsulation.
Results
Rat whole embryo culture
At the end of 48 h of culture, the morphometric parameters 
showed the absence of a general toxicity in any group except 
for 20000 IU NANO-A, were a significant reduction of the total 
score was evident (Table 1). By contrast, the two forms of vita-
min A were both able to induce specific abnormalities (Table 2). 
At the top concentrations (40000 IU BULK-A) and in NANO-A 
10000 IU and 20000 IU groups a significant increase of embryos 
showing multiple abnormalities (plurimal formed embryos) was 
observed. Even if branchial arch abnormalities were recorded 
with a dose dependent trend both in BULK and NANO vita-
min A groups, branchial defects were less severe (reductions) 
after BULK exposure than in NANO-A groups (when fusions 
were recorded) (Table 2). Different branchial arch phenotypes 
are shown in Figure 1. Encephalic abnormalities (open neural 
tube) were finally recorded only in NANO-A exposed groups 
(Table 2). BMD analysis showed that NANO-A was nearly 7 
times more effective in inducing abnormalities than BULK-A.
Figure 1: Morphological appearance of rat embryos after 48 h of cul-
ture: phenotypes observed in different samples. 
A, A’: Rat embryo after 48 h of culture showing anormal phenotype. 
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Note the dorsal region of the embryo (s), the heart (h), the cephalic region with the optic (>), the otic (°) vesicles and the branchial apparatus with 
the first (I), second (II), and third (III) separated branchial arches. Magnification: 20X (A), 40X (A’).
B: Plurimalformed embryo with complete fusion of the branchial arches (black rectangle). Magnification 20X. 
C: Embryo with reduced branchial arches. Note the extreme reduction of the first branchial arch (I). Magnification: 40X.
D: Embryo with total fusion of the branchial arches forming a unique anterior structure (§).Magnification: 40X.
E: Embryo with fused branchial arches forming a continuous structure (*).Magnification: 40X. Note the open neural tube (>>).
Table 1: Embryonic morphometric parameters recorded in rat embryos after 48 h of culture (MEAN ± SD)
CON+ETH BULK A 20000 BULK A 40000
Yolk sac diameter (mm) 3.67±0.4 3.93±0.19 3.79±0.26
9 12 9
Somite number 23.56±2.35 23.25±1.36 22.78±1.86
9 12 9
Total score 38.67±1.22 37.67±1.15 22.78±1.86
9 12 9
CON NANO A 2500 NANO A 10000 NANO A 20000
Yolk sac diameter (mm) 3.76 ± 0.21 3.86 ± 0.18 3.59 ± 0.2 3.68 ± 0.26
13 9 8 12
Somite number 23.38 ± 2.02 22.44 ± 2.79 22 ± 2 21.2 ± 1.81
13 9 9 10
Total score 37.92 ± 1.71 36.22 ± 1.3 37.11 ± 1.17 34.6 ± 4.14 ** ##
13 9 9 10
** p<0.01 vs. CON (ANOVA followed by Tukey’s test) ## p<0.01 vs. BULK A 20000 (Student’s T test)
Table 2: Abnormalities observed in rat embryos after 48 h of culture (%)
CON+ ETH BULK A 20000 BULK A 40000
Total examined 9 12 14
Abormal  ** 0 17 79
Plurimalformed embryos  ** 0 0 36
Embryos with BA abnormalities  ** 0 17 43
                              Reduced BA  ** 0 17 43
                              Fused BA 0 0 0
Encephalon abnormalities 0 0 0
CON NANO A 2500 NANO A 10000 NANO A 20000
Total examined 13 9 10 13
Abormal  ** 0 11 100 100 #
Plurimalformed embryos  ** 0 0 10 38 #
Embryos with BA abnormalities  ** 0 11 90 62 #
                               Reduced BA 0 11 0 0 #
                               Fused BA  ** 0 0 90 62 #
Encephalon abnormalities  ** 8 0 90 100 #
** p<0.01, Chi-squared test for trend 
# p<0.01 vs. BULK A 20000 (Chi-square test)  
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Figure 2: Evaluation of the relative potency factor (RPF) of the na-
no-formulation (dose-response curve with triangles) in respect to the 
bulk form (dose-response curve with circles) of vitamin A in WEC. RPF 
was calculated at the effective concentration at 50% (EC50). RPF of 
the nano-encapsulated vitamin A was 7.53 (BMD modelling by using 
PROAST software).
FETAX
Controls and X. laevis larvae exposed from NF stage 13 to NF 
stage 26 to the BULK and the NANO form of vitamin A at the 
end of the test reached NF stage 46. No abnormalities were re-
corded in larvae exposed to the BULK form of vitamin A (Table 
3).On the contrary, the exposure to NANO-A resulted effective 
in inducing oral abnormalities in a concentration-dependent 
manner, with a significant linear trend (p<0.0001). Abnormal 
larvae showed a marked reduction of the oral opening (after car-
tilage staining this picture has been related to a general reduction 
of cartilaginous oral structures) or a funnel shaped mouth(due 
to a total fusion of the anterior cartilaginous elements) (Table 
3, Figure 3). The BMD approach was not applicable due to the 
absence of abnormalities in the BULK-A groups.
Figure 3: Morphological appearance of NF stage 46 larvae. Magnifica-
tion: 16X (A-C), 20X (D-F).
A: dorsal view of a larva with a normal phenotype. Note the dorsalneu-
ral tube (NT), the well-expanded gill basket (G), eyes (*) and the oral 
opening (arrow).
B: dorsal view of a larva with reduced oral opening (arrow). 
C: dorsal view of a larva with a funnel-shape mouth (arrow).
D, D’: ventral view of head cartilagesisolated from a normal larva. D’ 
shows the scheme of normal cartilaginous structures. Note the ventral 
cartilaginous structure is ceratohyal (Ce), maxilla (+) and mandibular 
arch (§).
E: ventral view of head cartilages isolated from a larva with reduced 
oral opening. Note the bent mandibular arch (>).
F: ventral view of head cartilages isolated from a larva with fun-
nel-shaped oral opening. Note the complete fusion of the anterior car-
tilages (>>).
Table 3: Abnormalities observed in X. laevis larvae  (%).  
CON+ETH BULK A 10000 BULK A 20000 BULK A 40000
Total examined 28 19 25 27
Abnormal       0 0 0 0
                Reduced oral opening 0 0 0 0
                Fused oral cartilages 0 0 0 0
CON NANO A 5000 NANO A 10000 NANO A 20000 NANO A 40000
Total examined 55 18 18 29 39
Abnormal ** 0 0 0 6 # 18 §
                Reduced oral opening ** 0 0 0 6 # 10 §
                Fused oral cartilages ** 0 0 0 0 8 §
** p<0.01, Chi-squared test for trend # p<0.05 vs. BULK A 20000 (Chi-square test) § p<0.01 vs. BULK A 40000 (Chi-square test) 
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Neural crest cell migration evaluation (whole mount CRAB-
PI immunostaining)
After CRABPI immune staining, normal rat embryos at the end 
of the culture showed the stained tissue distributed in the fron-
to-nasal region, in the welding edge of the neural tube, around 
the optic and otic vesicle and in the pharyngeal area. Three dis-
tinct migratory flows of migrating cells were well distinguish-
able from the rhombencephalon to the branchial arches, where 
the ectomesenchyme appeared condensed (Figure 4). Embryos 
exposed to BULK-A 40000 IU/L showed normal neural crest 
cell distribution of immunostained tissues, whereas embryos ex-
posed to 20000 IU/L NANO-A showed a continuous immunos-
tained mass migrating from the hindbrain to the fused branchial 
arches (Figure 4). 
 Similarly to what observed in rat embryos, after immu-
nostaining of X. laevis embryos at stage 26, the immunostained 
tissues were distributed around the optic and otic vesicles, at the 
level of the frontal region and at the level of the branchial arches. 
Controls and embryos from 40000 IU/L BULK-A showeddis-
tinct migratory flows from the rhomboencephalon to the bran-
chial arches, while in embryos exposed to NANO-A40000 
IU/L a disorganization of the CRABPI positive tissues into the 
branchial regionwas observed (partially fused migration streams 
anda continuousbranchial immunostained mass) (Figure 4).
Figure 4: Rat embryos immunostained with antibody anti-CRABP af-
ter 48 h of culture (A-B’) and X. laevis embryos at NF stage 26 immu-
nostained with antibody anti-CRABP (C-D’). Magnification: 20X, 40X. 
On the right, schemes illustrating the skeletal elements derived from 
branchial neural crest cells in mammals and in amphibian larva.
A, A’: Normal embryo. Note the immunostained areas at the level of 
the optic and frontonasal region (asterisk), at the welding edges of the 
neural tube (>), at the level of the otic vesicle (o) and at the level of the 
branchial arches with three separate streams (arrows), indicating the 
migration of neural crest cells.
B, B’: rat embryo with fused branchial arches. Note the continuous 
mass (circle) at the level of the fusedbranchial arches.
C,C’: X. laevis embryo (control). Note the immunostained areas at the 
level of the frontal region (*), of the otic vesicle (>>), of the optic vesi-
cle (>),and at the level of the branchial arches with separate neural crest 
migratory flows (arrows). 
D, D’: X. laevis embryos exposed to NANO-A 40000. Note the altered 
migration of the neural crest cells:the migration streams appear fused 
forming a ventrally indistinct immunostained mass. 
Benchmark approachto compare NANO-A results in the two 
methods
BMD approach revealed that in WEC method NANO-A potency 
in inducing abnormalities was 14 times higher than the potency 
observed in FETAX (Figure 5). 
Figure 5: Evaluation of the relative potency factor of the effects of 
the nano-formulation of vitamin A in WEC (dose-response curve with 
triangles) in respect to FETAX (dose-response curve with circles). RPF 
of the effects nano-encapsulated vitamin A in WEC was 14 in respect to 
FETAX (BMD modelling by using PROAST software).
Discussion
The aim of the present work was to evaluate and compare the ef-
fects of bulk and nano-encapsulated vitamin A on embryo devel-
opment by using two different alternative models: the rat WEC 
and the X. laevis FETAX.The final goal was the identification of 
a rapid alternative test applicable in order to reconsider vitamin 
hazard evaluation after nano-encapsulation. Nano-encapsulation 
has greatly increased in food industry (nutraceutical production 
and human or veterinary food fortification), due to the many ad-
vantages that this recent technology confers to the encapsulated 
material[3,7]. Nevertheless, nano-encapsulation also raised some 
questions about the potential toxic effects of nano-encapsulated 
nutrients in food and beverages on human health. For these rea-
sons, EFSA and FDA promoted the search for valid alternative 
methods able to identify and evaluate the risks deriving from 
nanotechnologies[10]. Indeed, rat and Xenopus have already been 
proposed as animal models to assess the developmental toxicity 
of nano-molecules as well as the effects of nutrient excess or 
deficiency on embryos[27-33]. The reason stays in the interclass-
es similarities at the phylotypic stages (pharyngula, as named 
by Ballard[34]), corresponding in vertebrates to the neurulation 
and branchial arch organization stages) at both morphological 
and molecular level. This consideration constitutes the basis for 
the use of simple culture systems, enabling the in vitro develop-
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ment of low vertebrate whole embryos. In the present work, the 
nano-encapsulated vitamin A resulted effective in eliciting the 
specific developmental defects related to vitamin A exposure. 
NANO-A was effective in both models and induced quite similar 
neural crest cell-migration defects in embryos at the phylotypic 
stage (WEC at term of culture, FETAX at NF stage 26), WEC 
resulting more sensitive than FETAX. The teratogenic effect of 
hypervitaminosis A is not a novelty, and is known to be related 
to the increase of its active metabolite, RA.RA is a morphogen 
implicated in a wide range of biological processes during ani-
mal differentiation and morphogenesis[35]. This molecule is also 
implicated in cranio-facial morphogenesis, driving the correct 
differentiation of the branchial apparatus along the antero-pos-
terior axis. Our results with WEC model showed vitamin A-re-
lated branchial malformations similar to those previously re-
ported also by our group after RA exposure[23]. In rat embryos 
cultured in vitro, NANO-A resulted 7 times more effective than 
BULK-A, inducing more severeabnormalities as well. These re-
sults suggest a major bio-availability of the test molecule in the 
target sites. FETAX model results indicated that X. laevis em-
bryo is insensitive, during the morphogenetic phylotypic stages, 
to BULK-A. On the contrary, the highest NANO-A concentra-
tions caused specific cranio-facial abnormalitieswhich are quite 
similar to the anterior dysmorphogenesis observed in X. laevis 
exposed to exogenous RA[26,36,37]. This suggested that, also in X. 
laevis, the teratogenic action of NANO-A could depend on a 
perturbation of the RA pathway even if the effective concen-
trations are in the amphibian odel higher than those effective in 
WEC. The hypothesis of a perturbation in RA homeostasis is in 
agreement with data by Pennati et al.[38], who exposed ascidian 
embryos to bulk and nano-vitamin A and reportedalterations to 
ascidian anterior structures similar to those induced by Naga-
tomo et al.[39] by an excess of RA. In addition, the results ob-
tained onneural crest cell migration in both models (CRABPI 
immunostaining) support the hypothesis that the observed alter-
ations could be likely related to an increase of the endogenous 
RA levels. In fact, neural crest cell specification and migration 
from hindbrain to the branchial apparatus is driven by RA and 
exogenous RA exposure is known to induce similar migration 
defects both in rat and X. laevis models[40,41].
 The observed different sensitivity to vitamin A in the 
two models needs a further evaluation. The most plausible ex-
planation could be related to the fact that in nature preformed 
vitamin A itself (retinol) is only marginally accumulated in am-
phibian yolk egg deposits while the alternative carotenoid pre-
cursors are most abundant.
 Results from this work prompt the necessity to monitor 
the use of food supplemented with nano-vitamin A, suggesting 
that even low doses can elicit teratogenic effects due to its in-
creased bioavailability. Moreover, these data demonstrated that 
different animal models have different susceptibility to the ac-
tion of nano-encapsulated vitamin A and recommend to routine-
ly using more than one models when testing new formulations of 
molecules. 
 In conclusion, the collected data:1) confirm the tera-
togenic activity of hypervitaminosis A; 2) show that nano-en-
capsulation increases vitamin A embryotoxicity, probably acting 
on the vitamin bioavailability at target structure; 3) indicate a 
common target apparatus (branchial region and its cranio-facial 
derivatives) and a common dysmorphogenic pathway (neural 
crest cell migration alterations) in both the tested species; 4) sug-
gesta minor role of preformed vitamin A (retinol) in X. laevis de-
velopment if compared to mammal embryogenesis; 5) strongly 
suggest the need of hazard re-evaluation for nano-encapsulated 
vitamins devoted to human nutrition. 
Material and Method
Chemicals 
All analytical grade reagents, retinol palmitate (the esterified and 
biological active form of vitamin A- bulk A), Tyrode solution, 
3-amino-benzoic acid ethylester (MS222) and salts for FETAX 
solution were purchased from Sigma-Aldrich S.r.l., Italy. For 
the rat WEC, Nano A formula was dissolved in Tyrode solution, 
while for the amphibian, all suspensions and stock solutions 
were prepared in FETAX medium whose composition in mg/L 
was: 625 NaCl, 96NaHCO3, 30KCl, 15CaCl2 , 60CaSO4 • 2H2O, 
and 70 MgSO4). Nano-formulations with (NANO-A) or without 
(shell) encapsulated retinol palmitate were kindly provided by 
Aquanova® (Novasol® GmbH, Germany). For each experiment, 
solutions were freshly prepared and maintained in the dark.
Experimental design
Rat whole embryo culture: Virgin female Crl:CD rats (Charles 
River, Calco, Italy), housed in a thermostatically maintained 
room (T=22 ± 2C, relative humidity = 55 ± 5%) with a 12-h 
light cycle (light from 6:00AM to 6:00 PM), free access to food 
(4RF21, Charles River, Calco, Italy) and tap water, were caged 
overnight with males of proven fertility. The morning of posi-
tive vaginal smear was considered day 0 of gestation. 9.5 day 
old embryos (early neurula stage) were cultured according to 
the method proposed by New[42], partially modified by Giavini 
et al.[43]. Each culture flask contained heat inactivated rat serum 
(5 ml) and 5 embryos. Tested concentrations for BULK-A were 
dissolved in 100% ethanol and added (5 µl/bottle) to the culture 
medium of the treated group in order to obtain final concentra-
tions of five and ten times as the plasma concentration consid-
ered indicative of hypervitaminosis A (20000 IU/L and 40000 
IU/L). A control group (CON) and a control group containing 
the solvent alone (5 µl 100% ethanol/bottle, CON+ETH) were 
also performed. NANO-A has been supplied as a 10% emulsion 
of nanoliposomes, formed by a shell of lipids from soya lecithin 
and a core of retinol palmitate. NANO-A formula was dissolved 
in Tyrode solution and added to the culture medium in order to 
obtain final concentrations of 2500 IU/L, 10000 IU/L and 20000 
IU/L (concentrations determined by a preliminary range-finding 
test). A group exposed to the shell alone (dilutions equal to NA-
NO-A 20000 group) was evaluated during the range finding test 
and was unable to affect embryo development (data not shown). 
After 48 h of culture, embryos were morphologically examined 
under a dissecting microscope in order to evaluate morphomet-
rical parameters (yolk sac diameter, somite number, total score 
according to Brown and Fabro,[44] and any embryonic abnormal-
ity and then fixed in Dent’s fixative overnight at -20°C and pro-
cessed for immunostaining. 
FETAX methodology 
Adults of X. laevis (Harlan Italia, Bresso, Italy) were maintained 
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in controlled conditions (T = 20 ± 2°C; pH = 7.5 ± 0.5; Conduc-
tivity = 1000 ± 100 μS; 12h light/dark cycle) in an automatic 
breeding system (TecnoPlus, Techniplast, Italia) and fed a semi 
synthetic diet three times a week (XE40 by Mucedola; Settimo 
Milanese, Italy). Embryos were obtained from natural mating of 
couples, which were housed in well-aerated mating tanks over-
night. After mating, adults were removed and embryos collected 
in Petri dishes and processed according to Bacchetta et al.[45]. 
 Embryos were exposed from NF stage 13 (early neuru-
la stage) to NF stage 26 (phylotypic stage, corresponding to rat 
embryos at the end of the culture period)[46] to BULK-A (10000 
UI/L, 20000 UI/L and 40000 UI/L dissolved in 100% ethanol) 
or NANO-A (5000 UI/L, 10000 UI/L, 20000 UI/L and 40000 
UI/L dissolved in FETAX). BULK- and NANO-A concentra-
tions were selected based on a preliminary range finding test. A 
group exposed to the shell alone (dilutions equal to NANO-A 
40000 group) was evaluated during the range finding test and 
was unable to affect embryo development (data not shown). A 
control group (CON) and a control group containing the solvent 
alone (1 µl 100% ethanol /mL FETAX, CON+ETH) were also 
prepared. At NF stage 26, 5 embryos/group were fixed in 10% 
buffered formalin overnight at 4°C and processed for immu-
nostaining, while the remaining were removed from treatment 
solution, rinsed and incubated in FETAX solution till controls 
reached NF stage 46 (free swimming larva, end of the test). At 
this stage, all the surviving larvae were anaesthetized and then 
fixed for the subsequent morphological evaluation and cartilage 
staining. This assay was repeated three times under the same ex-
perimental conditions. To visualize the cartilage structures, fixed 
larvae were stained with Alcian Blue as previously described[46]. 
Immunostaining for CRABPI
In embryos exposed to the top concentrations, immunostaining 
of CRABPI was used to mark the migrating neural crest cells 
[48]. The whole mount immunostaining procedures on rat and 
X. laevis embryos have been previously described respectively 
in Menegola et al.[23] and Di Renzo et al.[47]. The monoclonal 
antibody was the anti-CRABPI (cellular retinoic acid binding 
protein), ABR, Italy, dilution 1:500. The anti-mouse-Ig-peroxi-
dase (Fab fragment Boehringer, Italy) was diluted 1:40 in PBS. 
Immuno-reactivity was visualized with the substrate 4-Cl-1-
naphtol (Sigma, Italy) and 0.006% H2O2. Stained cells appeared 
dark brown at light microscope. Negative control was performed 
incubating embryos only with secondary antibody.
Statistical analysis
For both rat and X. laevis tests, each assay was performed in 
triplicate. Data, expressed in percentage of malformed sam-
ples, were analyzed by Chi-square test. Data expressed as mean 
and standard deviation were analyzed by ANOVA followed by 
Tukey’s test or by Student’s T test. The level of significance was 
set at p < 0.05.
Benchmark-dose analysis
Benchmark-dose (BMD) approach was applied on abnormali-
ties. Data were modelled by using PROAST 65.2 software in 
order to characterize the single dose response curves and obtain 
the relative potency factor (RPF) of nano-versus bulk- vitamin A 
and in order to compare the results obtained in the two models.
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